Odyssey Health, Inc. f/k/a Odyssey Group International, Inc., a medical technology company focused on developing unique, life-saving medical products, announced its continued commitment to the newly formed entity, Odyssey NeuroPharma, with the expansion of its executive team. Joining the executive team at Odyssey Neuro Pharma to advance Odyssey's concussion treatment, and Niemann-Pick treatment, is Erik Emerson as Chief Commercial Officer and Greg Gironda as Chief Operating Officer. Mr. Emerson and Mr. Gironda have over 50 years of collective pharmaceutical experience in commercializing innovative pharmaceutical compounds with leading pharmaceutical companies.

Concussions effect all segments of society, with over 5 million occurrences annually in the U.S. alone. Currently, there are no FDA approved treatments available. Odyssey Neuropharma is planning a Phase II program, which will evaluate efficacy in support of its extensive safety and animal data.